Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has added Michael Raimondo to its advisory board. Raimondo, a 30-year veteran in the medical and pharmaceutical industries, brings extensive leadership experience and a track record of over $500 million in sales contracts. His initial focus will be on Venowave sales and business development.
Raimondo's expertise in sales negotiations and strategic account management is expected to boost Therma Bright's efforts in expanding its health-tech and med-tech device sales, particularly Venowave. The company is awaiting approval for patient reimbursement permanent codes from the U.S. Centers of Medicare and Medicaid (CMS) for Venowave, which could potentially benefit the 900,000 U.S. citizens who suffer from deep vein thrombosis annually.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha aggiunto Michael Raimondo al suo consiglio consultivo. Raimondo, con 30 anni di esperienza nelle industrie medica e farmaceutica, porta con sé un'ampia esperienza di leadership e un curriculum che vanta oltre 500 milioni di dollari in contratti di vendita. Il suo obiettivo iniziale sarà concentrato sulle vendite e sviluppo commerciale di Venowave.
Si prevede che l'expertise di Raimondo nelle negoziazioni di vendita e nella gestione di account strategici potenzi gli sforzi di Therma Bright nell'espandere le vendite dei suoi dispositivi health-tech e med-tech, in particolare Venowave. L'azienda è in attesa dell'approvazione dei codici permanenti per il rimborso ai pazienti da parte dei Centri statunitensi per Medicare e Medicaid (CMS) per Venowave, che potrebbe beneficiare potenzialmente 900.000 cittadini statunitensi che soffrono annualmente di trombosi venosa profonda.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ha añadido a Michael Raimondo a su junta asesora. Raimondo, con 30 años de experiencia en las industrias médica y farmacéutica, aporta una amplia experiencia en liderazgo y un historial de más de 500 millones de dólares en contratos de ventas. Su enfoque inicial estará en las ventas y desarrollo comercial de Venowave.
Se espera que la experiencia de Raimondo en negociaciones de ventas y gestión de cuentas estratégicas impulse los esfuerzos de Therma Bright para expandir sus ventas de dispositivos de health-tech y med-tech, particularmente Venowave. La empresa está a la espera de la aprobación de códigos permanentes de reembolso para pacientes por parte de los Centros de Servicios de Medicare y Medicaid de EE. UU. (CMS) para Venowave, lo que podría beneficiar potencialmente a 900,000 ciudadanos estadounidenses que sufren de trombosis venosa profunda anualmente.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)는 Michael Raimondo를 자문위원회에 추가했습니다. Raimondo는 의료 및 제약 산업에서 30년의 경력을 가진 전문가로, 5억 달러 이상의 계약 판매 실적과 광범위한 리더십 경험을 보유하고 있습니다. 그의 초기 초점은 Venowave 판매 및 비즈니스 개발에 맞춰질 것입니다.
Raimondo의 영업 협상 및 전략적 계좌 관리에 대한 전문 지식은 Therma Bright의 health-tech 및 med-tech 장비 판매, 특히 Venowave의 확장을 촉진할 것으로 기대됩니다. 회사는 Venowave에 대한 환자 상환을 위한 영구 코드의 승인을 미국 메디케어 및 메디케이드 센터 (CMS)로부터 기다리고 있으며, 이는 매년 심부정맥 혈전증으로 고통받는 90만 미국 시민에게 잠재적으로 혜택을 줄 수 있습니다.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) a ajouté Michael Raimondo à son conseil consultatif. Raimondo, avec 30 ans d'expérience dans les secteurs médical et pharmaceutique, apporte une vaste expérience en leadership et un parcours de plus de 500 millions de dollars en contrats de vente. Son objectif initial sera axé sur les ventes et le développement commercial de Venowave.
Il est attendu que l'expertise de Raimondo en matière de négociations de vente et de gestion de comptes stratégiques renforce les efforts de Therma Bright pour étendre ses ventes de dispositifs de santé et de technologie médicale, en particulier Venowave. L'entreprise attend l'approbation de codes de remboursement permanents pour les patients de la part des Centres américains pour Medicare et Medicaid (CMS) pour Venowave, ce qui pourrait potentiellement bénéficier à 900 000 citoyens américains qui souffrent annuellement de thrombose veineuse profonde.
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) hat Michael Raimondo in seinen Beratungsausschuss aufgenommen. Raimondo, ein 30-jähriger Veteran der medizinischen und pharmazeutischen Industrie, bringt umfangreiche Führungserfahrung und eine Erfolgsbilanz von über 500 Millionen Dollar in Verkaufsverträgen mit. Sein anfänglicher Fokus wird auf Venowave-Verkäufen und Geschäftsentwicklung liegen.
Raimondos Expertise in Verkaufsverhandlungen und strategischem Account Management wird voraussichtlich die Bemühungen von Therma Bright unterstützen, den Verkauf von Gesundheits- und Medizintechnikgeräten, insbesondere Venowave, auszubauen. Das Unternehmen wartet auf die Genehmigung für dauerhafte Erstattungscodes von den US-Zentren für Medicare und Medicaid (CMS) für Venowave, was potenziell 900.000 US-Bürger zugutekommen könnte, die jährlich an tiefen Venenthrombosen leiden.
- Addition of Michael Raimondo, a 30-year industry veteran, to the advisory board
- Raimondo's track record of over $500 million in sales contracts
- Pending approval for Venowave patient reimbursement permanent codes from U.S. CMS
- Existing value-added reseller partners ready to engage medical practitioner networks
- Potential market of 900,000 U.S. citizens suffering from deep vein thrombosis annually
- None.
New Advisory Board Member Will Initially Focus On Venowave Sales & Business Development
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce the Company has added Michael Raimondo, a 30-year veteran in sales and operations within the medical and pharmaceutical industries to its advisory board.
With more than three (3) decades of experience, Mr. Raimondo brings to the table extensive leadership experience including numerous accomplishments in developing industry-leading strategic account organizations that have delivered customer-centric solutions to healthcare systems across the USA. Mr. Raimondo specializes in sales negotiations, which has successfully led to over
Michael is a current Board of Advisor for Marketsmith, one of the country's (US) largest woman-owned and operated independent media and marketing agencies. He also is a Managing Partner of The Potentia Group, which specializes in negotiations training, sales leadership development and consulting within the U.S. healthcare market. Michael has a BS in physics and minor in mathematics from Kutztown University, and has served on the board of the Make A Wish Foundation for the Ohio-Kentucky-Indiana region.
"We are pleased that Michael has agreed to join Therma Bright's Advisory Board, where his skills and experience in sales and operations will aid in the Company's sales efforts of its health-tech and med-tech devices, including Venowave," shared Rob Fia, CEO of Therma Bright. "With our Venowave's pending approval on patient reimbursement permanent codes from the U.S. Centers of Medicare and Medicaid (CMS) and a handful of value-added reseller partners ready to engage their medical practitioner networks, we believe Michael will help expand these efforts and open more doors with other reseller partners across the U.S."
"I am excited to join Therma Bright's Advisory Board, and bring my sales, business development and operations experience to the Company," expressed Michael Raimondo. "With over 30 years of experience in medical and pharmaceutical industries, I am confident in my abilities to help grow the Company's value-added resellers across America to bring new, innovative solutions, like Venowave, to patient suffering from various pains and ailments, such as the 900,000 citizens who suffer from deep vein thrombosis each year per the US CDC."
Mr. Raimondo is taking on his advisory role at Therma Bright with great enthusiasm and has already begun actively tapping into his network to introduce Venowave pre-CMS approval.
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219742
FAQ
Who is Michael Raimondo and why did Therma Bright (TBRIF) add him to their advisory board?
What is Venowave and how does it relate to Therma Bright's (TBRIF) business?
How many people in the U.S. suffer from deep vein thrombosis annually, according to Therma Bright's (TBRIF) press release?
What is the current status of Venowave's approval process with the U.S. Centers of Medicare and Medicaid (CMS) for Therma Bright (TBRIF)?
